Abstract
Background The Coronavirus disease 2019 (Covid-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has prompted accelerated vaccines development. Their use was prioritized to protect the most vulnerable, notably, the elderly. Because of fluctuations in vaccine availability, strategies such as delayed second dose and heterologous prime-boost have been employed. The effectiveness of these strategies in the frail elderly are unknown.
Methods In this real-world vaccination study, under a government-decreed rationing strategy, elderly adults residing in long-term care facilities, with or without previously-documented SARS-CoV-2 infection, were administered homologous or heterologous mRNA vaccines, with an extended 16-week interval between doses. Clinical data and blood were serially collected during and after this interval period. Sera were tested for SARS-CoV-2-specific IgG antibodies (to trimeric S; RBD; nucleocapsid) by automated chemiluminescent ELISA.
Findings After a significant increase 4 weeks post-prime dose, there was a significant decline in anti-RBD and anti-S IgG levels until the boost dose, followed by an increase 4 weeks later. Previously uninfected individuals exhibited lower antibody responses up to 16 weeks post-prime dose, but achieved comparable levels to previously infected counterparts by 4 weeks post-second dose. Individuals primed with BNT162b2 exhibited larger decrease in anti-RBD and anti-S IgG levels with 16-week interval between doses, compared to those who received mRNA-1273. No differences in antibody levels 4 weeks after the second dose were noted between the two vaccines, in either homologous or heterologous combinations.
Interpretations These interim results of this ongoing longitudinal study show that, among frail elderly, neither age, sex, nor comorbidity affect antigenicity of mRNA-based COVID vaccines, but previous SARS-CoV-2 infection and type of mRNA vaccine influenced antibody responses when used with a 16-week interval between doses. Homologous/heterologous use of mRNA vaccines was not associated with significant differences in antibody responses 4 weeks following second dose, supporting their interchangeability.
Funding This project was supported by funding from the Public Health Agency of Canada, through the Vaccine Surveillance Reference group and the COVID-19 Immunity Task Force (CITF).
Competing Interest Statement
DCV is funded by Fonds de la recherche en santé du Québec clinician-scientist scholar Junior 2 program. DCV has received clinical trial support from: Cidara Therapeutics; CSL Behring; and Janssen Pharmaceuticals. DCV has served on advisory boards for: CSL Behring; Novartis Canada; and UCB Biosciences GmbH. DCV has received speaker honoraria from: CSL Behring; Merck Canada. DCV has a patent application pending (Electronic Filing System ID: 40101099) and a report of invention to McGill University (Track code: D2021-0043), both unrelated to this work. JPG is funded by a Canada Research Chair award. Production of COVID-19 reagents was financially supported by NRC's Pandemic Response Challenge Program.
Clinical Trial
prospective observational cohort study
Funding Statement
This project was supported by funding from the Public Health Agency of Canada through the COVID-19 Immunity Task Force (CITF) and by a COVID-19 Rapid Response grant from the Canadian Institute of Health Research (CIHR; #VR2 - 172722) and by a grant supplement by the CITF to M-A Langlois. Production of COVID-19 reagents was financially supported by the NRC's Pandemic Response Challenge Program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted in 12 LTC facilities of the Montréal Centre-Sud - Integrated University Health and Social Services Centre (CIUSSS du Centre-Sud-de-l'Île-de-Montréal) and was approved by its research ethics board (Comité d'éthique de la recherche Vieillissement-Neuroimagerie, protocol number 20-21-36 MP).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosures: DCV is funded by Fonds de la recherche en santé du Québec clinician-scientist scholar Junior 2 program. DCV has received clinical trial support from: Cidara Therapeutics; CSL Behring; and Janssen Pharmaceuticals. DCV has served on advisory boards for: CSL Behring; Novartis Canada; and UCB Biosciences GmbH. DCV has received speaker honoraria from: CSL Behring; Merck Canada. DCV has a patent application pending (Electronic Filing System ID: 40101099) and a report of invention to McGill University (Track code: D2021-0043), both unrelated to this work. JPG is funded by a Canada Research Chair award. Production of COVID-19 reagents was financially supported by NRC’s Pandemic Response Challenge Program.
Data Availability
De-identified clinical data for the patients in this study might be made available to other investigators after approval by the institutional review board. Requests should be directed to the corresponding author.
